Effect of Intermittent Pressure in Patients With PAD
Primary Purpose
Peripheral Arterial Disease
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Active Intermittent Negative Pressure (INP)
Placebo Intermittent Negative Pressure (INP)
Sponsored by
About this trial
This is an interventional basic science trial for Peripheral Arterial Disease focused on measuring PAD
Eligibility Criteria
Inclusion Criteria
PAD Patients:
- Age ≥ 18 years
- Attending vascular outpatient clinics or admitted in ward with PAD.
- ABPI <0.9
Healthy Volunteers:
- Age ≥ 18 years
- No current or previous significant cardiovascular illness
- Able to give written informed consent
Exclusion criteria
PAD Patients:
- Unable to give written informed consent
- Patients with deep venous thrombosis
- Pregnant women
Healthy Volunteers:
- Positive medical history of: Vascular diseases such as PAD, stroke, IHD, hypertension... etc.
- Haematological conditions such as hypercoagulability, deep venous thrombosis... etc.,
- Alcohol excess
- Unable to give written informed consent
- Pregnant women
Sites / Locations
- School of Medicine, University of Dundee, Ninewells Hospital & Medical School
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Active PAD group
Placebo PAD group
Healthy Volunteers
Arm Description
-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
-40 mmHg of Intermittent Negative Pressure (INP) for 5 days
Outcomes
Primary Outcome Measures
Change in microvascular blood flow
Microvascular blood flow measurement in foot using laser Dopper imaging.
Change in microvascular endothelial function
Peak blood perfusion response to acetylcholine (ACh) delivered by iontophoresis will be measured using a laser Doppler imager.
Change in arterial stiffness
Brachial pulse wave analysis (PWA) augmentation index (Ax) and carotid-femoral pulse wave velocity (m/s) (PWV) as an indication of arterial stiffness.
Change in macrovascular endothelial function
Brachial endothelial function measured as change in brachial blood vessel diameter (%) upon shear stress.
Secondary Outcome Measures
Change in pain score
Self-scoring of pain felt by patient on a visual analogue scale with 0 being no pain at all to 10 being the worst pain ever felt.
Change in concentration of blood borne inflammatory and oxidative stress biomarkers
Concentration of inflammatory and oxidative stress markers of endothelial activation/damage (including IL-1a, IL-6, IL-10, TNF-a, CRP, E-selectin and sICAM-1) measured in serum and plasma collected from patient blood samples.
Change in Ankle-Brachial Pressure Index (ABPI)
Brachial systolic pressure and ankle (dorsalis pedis) systolic pressure (mmHg) measured using Doppler probe. ABPI calculated as ankle systolic pressure divided by brachial systolic pressure.
ABPI <0.9 = PAD, ABPI =>1.0 Normal.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03854097
Brief Title
Effect of Intermittent Pressure in Patients With PAD
Official Title
Mechanistic Insights Into Changes in Blood Flow Following Application of Intermittent Negative Pressure
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
February 16, 2019 (Actual)
Primary Completion Date
June 5, 2021 (Actual)
Study Completion Date
June 5, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Dundee
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The study will evaluate the effect of intermittent negative pressure (INP) on peripheral arterial disease (PAD) patient vascular function and blood flow. Patients will be given either -40mmHg INP or -10mmHg INP which will act as a placebo. Healthy volunteers will be given -40mmHg INP to evaluate changes in vascular function and blood flow with INP in healthy physiology.
Detailed Description
Atherosclerosis occurs when blood supply to the lower limbs is restricted upon accumulation of fat in the arteries. Atheroslerosis in the lower limbs is termed peripheral arterial disease (PAD). The initial symptom is pain in the lower limbs followed by ulceration and gangrene. The literature has indicated that intermittent negative pressure (INP) can be used to reduce pain and facilitate wound healing. INP is a non-invasive technique that aims to increase arterial and skin blood flow in lower limbs and foot. This study aims to investigate the underlying mechanisms that are involved in changes in blood flow following application of INP. The Flow-Ox 'boot' will be used to apply INP for periods ranging from 4-8 weeks, for an hour twice per day, to the lower limb to determine the effects of INP on vascular function and blood flow. Specifically, vascular tests such as assessments of endothelial function, arterial stiffness, ankle-brachial pressure index (ABPI) and blood borne metabolic and inflammatory markers will be performed before and after INP application. A pain chart will be employed before and after INP application to determine whether there is any change in perception of pain felt by individuals who suffer from pain associated with lower limb arterial disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease
Keywords
PAD
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
65 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active PAD group
Arm Type
Experimental
Arm Description
-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
Arm Title
Placebo PAD group
Arm Type
Experimental
Arm Description
-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
Arm Title
Healthy Volunteers
Arm Type
Experimental
Arm Description
-40 mmHg of Intermittent Negative Pressure (INP) for 5 days
Intervention Type
Device
Intervention Name(s)
Active Intermittent Negative Pressure (INP)
Intervention Description
Application of -40mmHg negative pressure on the lower limb
Intervention Type
Device
Intervention Name(s)
Placebo Intermittent Negative Pressure (INP)
Intervention Description
Application of -10mmHg negative pressure on the lower limb
Primary Outcome Measure Information:
Title
Change in microvascular blood flow
Description
Microvascular blood flow measurement in foot using laser Dopper imaging.
Time Frame
Baseline, 1 day and 4-8 weeks
Title
Change in microvascular endothelial function
Description
Peak blood perfusion response to acetylcholine (ACh) delivered by iontophoresis will be measured using a laser Doppler imager.
Time Frame
Baseline, 1 day and 4-8 weeks
Title
Change in arterial stiffness
Description
Brachial pulse wave analysis (PWA) augmentation index (Ax) and carotid-femoral pulse wave velocity (m/s) (PWV) as an indication of arterial stiffness.
Time Frame
Baseline, 1 day and 4-8 weeks
Title
Change in macrovascular endothelial function
Description
Brachial endothelial function measured as change in brachial blood vessel diameter (%) upon shear stress.
Time Frame
Baseline, 1 day and 4-8 weeks
Secondary Outcome Measure Information:
Title
Change in pain score
Description
Self-scoring of pain felt by patient on a visual analogue scale with 0 being no pain at all to 10 being the worst pain ever felt.
Time Frame
Baseline, 1 day and 4-8 weeks
Title
Change in concentration of blood borne inflammatory and oxidative stress biomarkers
Description
Concentration of inflammatory and oxidative stress markers of endothelial activation/damage (including IL-1a, IL-6, IL-10, TNF-a, CRP, E-selectin and sICAM-1) measured in serum and plasma collected from patient blood samples.
Time Frame
Baseline, 1 day and 4-8 weeks
Title
Change in Ankle-Brachial Pressure Index (ABPI)
Description
Brachial systolic pressure and ankle (dorsalis pedis) systolic pressure (mmHg) measured using Doppler probe. ABPI calculated as ankle systolic pressure divided by brachial systolic pressure.
ABPI <0.9 = PAD, ABPI =>1.0 Normal.
Time Frame
Baseline, 1 day and 4-8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria
PAD Patients:
Age ≥ 18 years
Attending vascular outpatient clinics or admitted in ward with PAD.
ABPI <0.9
Healthy Volunteers:
Age ≥ 18 years
No current or previous significant cardiovascular illness
Able to give written informed consent
Exclusion criteria
PAD Patients:
Unable to give written informed consent
Patients with deep venous thrombosis
Pregnant women
Healthy Volunteers:
Positive medical history of: Vascular diseases such as PAD, stroke, IHD, hypertension... etc.
Haematological conditions such as hypercoagulability, deep venous thrombosis... etc.,
Alcohol excess
Unable to give written informed consent
Pregnant women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jody McIntosh
Organizational Affiliation
PhD student
Official's Role
Principal Investigator
Facility Information:
Facility Name
School of Medicine, University of Dundee, Ninewells Hospital & Medical School
City
Dundee
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Intermittent Pressure in Patients With PAD
We'll reach out to this number within 24 hrs